Answers are grounded in this paper and cite their sources.
Randomized trials demonstrate higher 12-week response rates with adalimumab in hidradenitis suppurativa, indicating therapeutic efficacy without added serious adverse events.
Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups. (Funded by AbbVie; ClinicalTrials.gov numbers, NCT01468207 and NCT01468233 for PIONEER I and PIONEER II, respectively.).
No takes yet. Share an insight, caveat, or question.
Kimball et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: